Консенсусное заключение по итогам междисциплинарного экспертного совета с международным участием по вопросам персонализированного назначения заместительной гормональной терапии/менопаузальной гормональной терапии у женщин в различные возрастные периоды

Значительное снижение уровня эстрогенов, обусловленное наступлением менопаузы, является причиной развития клинически значимых симптомов климактерического синдрома, существенно ухудшающих качество жизни, а также относится к факторам, повышающим долгосрочные кардиометаболические риски. Согласно действующим российским клиническим рекомендациям, менопаузальная гормональная терапия (МГТ) рассматривается в качестве наиболее эффективного метода коррекции климактерических расстройств.

Для проработки актуальных вопросов ведения пациенток в периодах перии постменопаузы и особенностей назначения МГТ в различных клинических ситуациях в последнем квартале 2025 г. был созван Междисциплинарный экспертный совет, основной задачей которого стала оптимизация научно обоснованных алгоритмов ведения пациенток с климактерическими/постовариоэктомическими синдромами. По итогам работы специалистами национального и международного уровня, представляющими различные области медицины, был утвержден консенсусный документ, регламентирующий принципы назначения заместительной/менопаузальной гормональной терапии женщинам с сопутствующей соматической патологией.

1. Delanerolle G., Phiri P., Elneil S., Talaulikar V., Eleje G.U., Kareem R. et al.; MARIE collaborative. Menopause: a global health and wellbeing issue that needs urgent attention. Lancet Glob. Health. 2025; 13(2): e196-e198. https://dx.doi.org/10.1016/S2214-109X(24)00528-X

2. WНО. Menopause. 2024. Available at: www.who.int/news-room/fact-sheets/detail/menopause

3. Burki T. Rossella Nappi: taking the stigma out of menopause. Lancet Diabetes Endocrinol. 2023; 11(4): 232. https://dx.doi.org/10.1016/S2213-8587(23)00057-8

4. Thavabalan K., Ovenell A., Pierce P., Sutaria A., Parkhouse A., Baydemir N. et al. Barriers to the safe discussion of the experience and management of menopausal symptoms: A systematic literature review. Maturitas. 2025; 201: 108683. https://dx.doi.org/10.1016/j.maturitas.2025.108683

5. Сметник А.А., Иванов И.А., Ермакова Е.И., Табеева Г.И. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. Акушерство и гинекология. 2025; 8: 196-208.

6. Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al.; (IMS Publication Steering Committee) and The IMS Recommendations Writing Group; IMS Recommendations Writing Group; With valuable support provided by. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025; 28(6): 634-656. https://dx.doi.org/10.1080/13697137.2025.2585487

7. Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784

8. Xia W., Khalil R.A. Hormone replacement therapy and cardiovascular health in postmenopausal women. Int. J. Mol. Sci. 2025; 26(11): 5078. https://dx.doi.org/10.3390/ijms26115078

9. Kim Y., Cho M.K., Chung Y.J., Hong S.H., Hwang K.R., Jeon G.H. et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025; 31(2): 53-84. https://dx.doi.org/10.6118/jmm.25103

10. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028

11. European Menopause and Andropause Society (EMAS). EMAS statement on the FDA decision to remove “Black Box” warnings from Menopausal Hormone Therapy (MHT). Available at: https://www.linkedin.com/pulse/emas-statement-fda-decision-remove-cpmgf

12. https://edition.cnn.com/2025/10/02/health/menopause-hrt-warning-change-makary

13. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213

14. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/10.1080/13697137.2020.1804547

15. Li X.T., Li P.Y., Liu Y., Yang H.S., He L.Y., Fang Y.G. et al. Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis. Qual Life Res. 2020; 29(1):19-36. https://dx.doi.org/10.1007/s11136-019-02326-2

16. Honigberg M.C., Zekavat S.M., Aragam K., Finneran P., Klarin D., Bhatt D.L. et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019; 322(24): 2411-21. https://dx.doi.org/10.1001/jama.2019.19191

17. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8.

18. https://www.who.int/ru/initiatives/decade-of-healthy-ageing

19. Mansour D., Barber K., Chalk G., Noble N., Digpal A.A.S., Talaulikar V. et al. The evolving perspective of menopause management in the United Kingdom. Womens Health (Lond). 2024; 20: 17455057241288641. )]. https://dx.doi.org/10.1177/17455057241288641

20. Наделяева Я.Г., Данусевич И.Н. Особенности менопаузы, осведомленность и качество жизни женщин, проживающих в городской и сельской местности. Доктор.Ру. 2025; 24(1): 81-7.

21. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025.

22. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020; 142(25): e506-e532. https://dx.doi.org/10.1161/CIR.0000000000000912

23. Stuenkel C.A. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2024; 27(1): 5-15. https://dx.doi.org/10.1080/13697137.2023.2259793

24. Thurston R.C., Aslanidou Vlachos H.E., Derby C.A., Jackson E.A., Brooks M.M., Matthews K.A. et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J. Am. Heart Assoc. 2021; 10(3): e017416. https://dx.doi.org/10.1161/JAHA.120.017416

25. Boardman H.M., Hartley L., Eisinga A., Main C., Roqué i Figuls M., Bonfill Cosp X. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015; 2015(3): CD002229. https://dx.doi.org/10.1002/14651858.CD002229.pub4

26. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409. https://dx.doi.org/10.1136/bmj.e6409

27. Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784

28. Oliver-Williams C., Glisic M., Shahzad S., Brown E., Pellegrino Baena C., Chadni M. et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum. Reprod. Update. 2019; 25(2): 257-71. https://dx.doi.org/10.1093/humupd/dmy039

29. Kalenga C.Z., Metcalfe A., Robert M., Nerenberg K.A., MacRae J.M., Ahmed S.B. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. Hypertension. 2023; 80(7):1463-73. https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19938

30. Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N. et al.; ACC CVD in Women Committee. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023; 147(7): 597-610. https://dx.doi.org/10.1161/CIRCULATIONAHA.122.061559

31. Mueck A.O., Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005; 3(1): 45-54. https://dx.doi.org/10.2174/1568016052773270

32. Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32.

33. Straczek C., Oger E., Yon de Jonage-Canonico M.B., Plu-Bureau G., Conard J., Meyer G. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500. https://dx.doi.org/10.1161/CIRCULATIONAHA.105.565556

34. Olié V., Canonico M., Scarabin P.Y. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr. Opin. Hematol. 2010; 17(5): 457-63. https://dx.doi.org/10.1097/MOH.0b013e32833c07bc

35. Mohammed K., Abu Dabrh A.M., Benkhadra K., Al Nofal A., Carranza Leon B.G., Prokop L.J. et al. Oral vs Transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100(11): 4012-20. https://dx.doi.org/10.1210/jc.2015-2237

36. Зотова И.В., Затейщиков Д.А. Наследственная тромбофилия и венозные тромбоэмболические осложнения: правила тестирования в клинической практике. Российский кардиологический журнал. 2020; 25(3S): 4024.

37. Dicks A.B., Moussallem E., Stanbro M., Walls J., Gandhi S., Gray B.H. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J. Clin. Med. 2024; 13(2): 362. https://dx.doi.org/10.3390/jcm13020362

38. Rovinski D., Ramos R.B., Fighera T.M., Casanova G.K., Spritzer P.M. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb. Res. 2018; 168: 83-95. https://dx.doi.org/10.1016/j.thromres.2018.06.014

39. Royal College of Obstetricians & Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: Acute management. Green-top Guideline No. 37b. London: RCOG; 2015.

40. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2018; 132(1): e18-e34. https://dx.doi.org/10.1097/AOG.0000000000002703

41. Alnor A.B., Gils C., Vinholt P.J. Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis. Ann. Hematol. 2024; 103(10): 4285-94. https://dx.doi.org/10.1007/s00277-024-05926-2

42. Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008; 336(7655): 1227-31. https://dx.doi.org/10.1136/bmj.39555.441944.BE

43. Folsom A.R., Aleksic N., Wang L., Cushman M., Wu K.K., White R.H. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler. Thromb. Vasc. Biol. 2002; 22(6): 1018-22. https://dx.doi.org/10.1161/01.atv.0000017470.08363.ab

44. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet. Gynecol. 2013; 121(4): 887-90. https://dx.doi.org/10.1097/01.AOG.0000428645.90795.d9

45. https://thebms.org.uk/wp-content/uploads/2025/04/09-BMS-TfC-NICE-Menopause-Menopause-identification-and-management-%E2%80%93-from-guideline-to-practice-MARCH2025-D.pdf

46. Lumsden M.A., Dekkers O.M., Faubion S.S., Lindén Hirschberg A., Jayasena C.N., Lambrinoudaki I. et al. European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025; 193(4): G49-G81. https://dx.doi.org/10.1093/ejendo/lvaf206

47. Asmis L., Hellstern P. Thrombophilia testing - a systematic review. Clin. Lab. 2023; 69(4). https://dx.doi.org/10.7754/Clin.Lab.2022.220817

48. Douketis J.D., Julian J.A., Kearon C., Anderson D.R., Crowther M.A., Bates S.M. et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J. Thromb. Haemost. 2005; 3(5): 943-8. https://dx.doi.org/10.1111/j.1538-7836.2005.01268.x

49. Middeldorp S., Nieuwlaat R., Baumann Kreuziger L., Coppens M., Houghton D., James A.H. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023; 7(22): 7101-38. https://dx.doi.org/10.1182/bloodadvances.2023010177

50. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.642280

51. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https://dx.doi.org/10.1136/bmj.k4810

52. Hicks A., Robson D., Tellis B., Smith S., Dunkley S., Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025; 28(5): 497-509. https://dx.doi.org/10.1080/13697137.2025.2503874

53. Renoux C., Dell'Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86. https://dx.doi.org/10.1111/j.1538-7836.2010.03839.x

54. Canonico M., Fournier A., Carcaillon L., Olié V., Plu-Bureau G., Oger E. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5. https://dx.doi.org/10.1161/ATVBAHA.109.196022

55. Sweetland S., Beral V., Balkwill A., Liu B., Benson V.S., Canonico M. et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012; 10(11): 2277-86. https://dx.doi.org/10.1111/j.1538-7836.2012.04919.x

56. Manson J.E., Kaunitz A.M. Menopause management--getting clinical care back on track. N. Engl. J. Med. 2016; 374(9): 803-6. https://dx.doi.org/10.1056/NEJMp1514242

57. Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018; 21(4): 346-54. https://dx.doi.org/10.1080/13697137.2018.1455657

58. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166

59. Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1-14. https://dx.doi.org/10.1016/j.maturitas.2022.04.008

60. Menopause: identification and management. London: National Institute for Health and Care Excellence (NICE); 2024 Nov 7.

61. Genazzani A.R., Divakar H., Khadilkar S.S., Monteleone P., Evangelisti B., Galal A.F. et al. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int. J. Gynaecol. Obstet. 2024; 164(2): 516-30. https://dx.doi.org/10.1002/ijgo.15278

62. Ayzenberg I., Katsarava Z., Sborowski A., Chernysh M., Osipova V., Tabeeva G. et al.; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012; 32(5): 373-81. https://dx.doi.org/10.1177/0333102412438977

63. Welch K.M., Brandes J.L., Berman N.E. Mismatch in how oestrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol. Sci. 2006; 27 Suppl 2: S190-2. https://dx.doi.org/10.1007/s10072-006-0599-6

64. Ravi V., Osouli Meinagh S., Bavarsad Shahripour R. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Front. Neurol. 2024; 15: 1435208. https://dx.doi.org/10.3389/fneur.2024.1435208

65. Scottish Government Women’s Health and Heart Health Policy Teams with thanks to the numerous clinicians who helped and in collaboration with the medical advisory council of the British Menopause Society. Management of menopause for women with cardiovascular disease. Post Reprod. Health. 2024; 30(4): 280-4. https://dx.doi.org/10.1177/20533691241302040

66. Ali N., Sohail R., Jaffer S.R., Siddique S., Kaya B., Atowoju I. et al. The role of estrogen therapy as a protective factor for Alzheimer's disease and dementia in postmenopausal women: a comprehensive review of the literature. Cureus. 2023; 15(8): e43053. https://dx.doi.org/10.7759/cureus.43053

67. Maki P.M., Jaff N.G. Brain fog in menopause: A health-care professional's guide for decision-making and counseling on cognition. Climacteric. 2022; 25(6): 570-8. https://dx.doi.org/10.1080/13697137.2022.2122792

68. Garber J.R., Cobin R.H., Gharib H., Hennessey J.V., Klein I., Mechanick J.I. et al.; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012; 22(12): 1200-35. https://dx.doi.org/10.1089/thy.2012.0205

69. Mintziori G., Veneti S., Poppe K., Goulis D.G., Armeni E., Erel C.T. et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024; 185: 107991. https://dx.doi.org/10.1016/j.maturitas.2024.107991

70. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гипотиреоз. 2025.

71. Kaminski J., Junior C.M., Pavesi H., Drobrzenski B., Amaral G.M.D. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial. Menopause. 2021; 28(9): 1044-52. https://dx.doi.org/10.1097/GME.0000000000001811

72. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92(2): 399-404. https://dx.doi.org/10.1210/jc.2006-0513

73. International Diabetes Federation. Diabetes Atlas. 11th Edition – 2025. Available at: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025-1.pdf

74. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204-21.

75. Rossi R., Origliani G., Modena M.G. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004; 27(3): 645-9. https://dx.doi.org/10.2337/diacare.27.3.645

76. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54. https://dx.doi.org/10.1111/j.1463-1326.2005.00545.x

77. WHO. Obesity and overweight. 8 December 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

78. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027-50. https://dx.doi.org/10.1016/S0140-6736(23)02750-2

79. Giannini A. Menopause, hormone replacement therapy (HRT) and obesity. Curr. Res. Diab. Obes. J. 2018; 7(1): 555704. https://dx.doi.org/10.19080/CRDOJ.2018.07.555704

80. Powell-Wiley T.M., Poirier P., Burke L.E., Després J.P., Gordon-Larsen P., Lavie C.J. et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021; 143(21): e984-e1010. https://dx.doi.org/10.1161/CIR.0000000000000973

81. Hotoleanu C. Association between obesity and venous thromboembolism. Med. Pharm. Rep. 2020; 93(2):162-8. https://dx.doi.org/10.15386/mpr-1372

82. Beaudart C., Zaaria M., Pasleau F., Reginster J.Y., Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017; 12(1): e0169548. https://dx.doi.org/10.1371/journal.pone.0169548

83. Palacios S., Chedraui P., Sánchez-Borrego R., Coronado P., Nappi R.E. Obesity and menopause. Gynecol. Endocrinol. 2024; 40(1): 2312885. https://dx.doi.org/10.1080/09513590.2024.2312885

84. O'Sullivan A.J., Crampton L.J., Freund J., Ho K.K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 1998; 102(5): 1035-40. https://dx.doi.org/10.1172/JCI2773

85. Mukherjee A., Ghaem-Maghami S., Syed A.A. Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reprod. Health. 2025; 31(2): 127-31. https://dx.doi.org/10.1177/20533691251343069

86. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1): 230. https://dx.doi.org/10.1186/s12877-017-0621-2

87. Суджаева О.А. Проблема полипрагмазии при лечении сердечно-сосудистых заболеваний у лиц пожилого возраста: обзор Консенсуса экспертов рабочей группы Европейского общества кардиологов. Медицинские новости. 2022; 5: 20-6.

88. Gosselin M., Talbot D., Simard M., Chiu Y.M., Mésidor M., Boiteau V. et al. Classifying polypharmacy according to pharmacotherapeutic and clinical risks in older adults: a latent class analysis in Quebec, Canada. Drugs Aging. 2023; 40(6): 573-83. https://dx.doi.org/10.1007/s40266-023-01028-2

89. Юренева С.В. Менопаузальная гормональная терапия – индивидуализированный подход с позиции эффективности и безопасности: обзор международных рекомендаций. Акушерство и гинекология. 2024; 9: 36-46.

90. Rodriguez S., Gaunt T.R., Guo Y., Zheng J., Barnes M.R., Tang W. et al. Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array. Eur. J. Hum. Genet. 2016; 24(1): 106-12. https://dx.doi.org/10.1038/ejhg.2015.63

91. Cirillo D.J. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330. https://dx.doi.org/10.1001/jama.293.3.330

92. Liu B., Beral V., Balkwill A., Green J., Sweetland S., Reeves G.; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008; 337: a386.

93. https://dx.doi.org/10.1136/bmj.a386

94. Saddique MN, Saleem S, Shahid I, Javid S, Hamza Khan M, Iqbal J. The estrogengallstone connection: uncovering the pathways. Discov. Public Health. 2024;21:113. doi: https://dx.doi.org/10.1186/s12982-024-00232-8

95. Saddique M.N., Saleem S., Shahid I., Javid S., Hamza Khan M., Iqbal J. The estrogen gallstone connection: uncovering the pathways. Discov. Public Health. 2024; 21: 113. https://dx.doi.org/10.1186/s12982-024-00232-8